Phase 1/2a LYM1002 study of ibrutinib (ibr) + nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status Meeting Abstract
| Authors: | Hodkinson, B.; Schaffer, M.; Brody, J.; Jurczak, W.; Carpio, C.; Ben-Yehuda, D.; Avivi, I.; Saleem, R.; Ozcan, M.; Alvarez, J.; Ceulemans, R.; Fourneau, N.; Balasubramanian, S.; Younes, A. |
| Abstract Title: | Phase 1/2a LYM1002 study of ibrutinib (ibr) + nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status |
| Meeting Title: | 110th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 79 |
| Issue: | 13 Suppl. |
| Meeting Dates: | 2019 Mar 29-Apr 3 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-07-01 |
| Language: | English |
| ACCESSION: | WOS:000488279403421 |
| DOI: | 10.1158/1538-7445.Am2019-4024 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4024 -- Source: Wos |
